Study of SGR-1505 in Mature B-Cell Neoplasms

This study is looking for adults aged 18 and over who have been diagnosed with a specific type of B-cell lymphoma. This diagnosis must have been confirmed by medical tests. Importantly, your lymphoma needs to be what doctors call 'relapsed/refractory,' which means it hasn't responded well to previous treatments or it has come back after treatment. You also need to be fit enough for the study, with doctors checking your general health and that you have no more than mild symptoms preventing daily activities.

There are also some reasons why you might not be able to join. For example, if you need urgent cancer treatment right now, or if you've been diagnosed with another serious cancer in the last two years. If you're allergic to SGR-1505 or its ingredients, or if your lymphoma has spread to your brain or spinal cord and is causing symptoms, you wouldn't be able to take part. Researchers will also check if you have any other serious health conditions that could make taking the study drug risky.

If you decide to take part in this study, you will be given the study drug, SGR-1505, which is taken by mouth. You will have regular visits to the hospital or clinic at the beginning of the study, which will involve blood tests to check how your body is handling the drug and to look for any side effects. You will also have scans and other tests to see how your lymphoma is responding. The exact number of visits and tests will be explained to you by the study team, but they will be more frequent at the start and then may become less frequent if you continue on the study. Your health will be closely monitored throughout your time in the study and potentially for a period afterwards. The total time you might participate in the study will vary depending on your response to the treatment and the study's design.